Carolina Firacative1, Patricia Escandón2. 1. Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogota, 111221, Colombia. 2. Group of Microbiology, Instituto Nacional de Salud, Bogota, 111221, Colombia.
Abstract
Cryptococcosis by Cryptococcus gattii is endemic in Colombia, affecting mostly immunocompetent hosts. Since antifungal susceptibility differs between molecular types of cryptococcal isolates, as reported elsewhere, the aim of this study was to determine if 42 Colombian clinical isolates, VGI, VGII and VGIII, differ in the susceptibility to commonly used antifungals, using Sensititre plates. Among the molecular types, six non-wild type isolates to fluconazole, voriconazole, and 5-flucytosine, were identified. Besides, VGI and VGII were less susceptible to 5-flucytosine and azoles, respectively, than other molecular types. These findings support the applicability of practicing susceptibility testing, which could better guide treatment in cryptococcosis. LAY SUMMARY: Cryptococcosis gattii affects immunocompetent people. For a correct treatment, antifungal susceptibility testing is essential. This study shows differences in the susceptibility to commonly used antimycotics among genotypes of Colombian clinical C. gattii isolates, some of which are non-wild-type.
Cryptococcosis by Cryptococcus gattii is endemic in Colombia, affecting mostly immunocompetent hosts. Since antifungal susceptibility differs between molecular types of cryptococcal isolates, as reported elsewhere, the aim of this study was to determine if 42 Colombian clinical isolates, VGI, VGII and VGIII, differ in the susceptibility to commonly used antifungals, using Sensititre plates. Among the molecular types, six non-wild type isolates to fluconazole, voriconazole, and 5-flucytosine, were identified. Besides, VGI and VGII were less susceptible to 5-flucytosine and azoles, respectively, than other molecular types. These findings support the applicability of practicing susceptibility testing, which could better guide treatment in cryptococcosis. LAY SUMMARY: Cryptococcosis gattii affects immunocompetent people. For a correct treatment, antifungal susceptibility testing is essential. This study shows differences in the susceptibility to commonly used antimycotics among genotypes of Colombian clinical C. gattii isolates, some of which are non-wild-type.
Authors: Kyung J Kwon-Chung; James A Fraser; Tamara L Doering; Zhou Wang; Guilhem Janbon; Alexander Idnurm; Yong-Sun Bahn Journal: Cold Spring Harb Perspect Med Date: 2014-07-01 Impact factor: 6.915
Authors: Edmond J Byrnes; Robert J Bildfell; Sheryl A Frank; Thomas G Mitchell; Kieren A Marr; Joseph Heitman Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge Journal: Antimicrob Agents Chemother Date: 2012-09-04 Impact factor: 5.191